We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Https://www.bayer.com/en/us/news-stories/fda-breakthrough-therapy-designation#:~:text=Berlin%2C%20Germany%2C%20February%2026%2C,tumors%20have%20activating%20HER2%20(ERBB2)
https://twitter.com/Bayer/status/1762054925838606679
Yesterday, Physiomics reposted ( retweeted) a post from Bayer. The Bayer post was sent out om X on the 26th Feb 2024.
In the post, about pipeline and FDA granting Tyrosine Kinase inhibitor for non small cell lung cancer.
I have not followed Physiomics for as long as some here. Have PYC worked with Bayer in the past? Was it anything to do with the TK inhibitor? Just found it intriguing that out of nowhere, PYC repost Bayer, which i also think is a first?
Thanks Trench....very recent as written 18th March
With the US government’s unveiling of the Precision Medicine Initiative in 2015 and investing $215 million in the National Institutes of Health (NIH)’s 2016 budget—with an additional $54 million announced in 2023—precision medicine is now seen as a healthcare approach for both the present and the future, particularly with the explosion of personalized care delivery.
Good article issued recently by PYC partner DosemeRx on the future of Precision Medicine
https://www.pharmexec.com/view/precision-medicine-investments-and-outcomes-expected
Peter Sargent mentioned that there were 'some exciting developments around the Doseme partnership' and Jim commented in this regard to 'watch this space' Makes for an interesting update in due course
Record 1st half revenues ever
Losses down and breakeven due
Pipeline up 50% to £1.5mln
The Directors are pleased that the Company is on track to meet expectations, which, if achieved, would mean a significant increase in total income compared with the financial year ended 30 June 2023.
Ilovesushi
You went silent on CPX at 2p in Decemeber
You then returned to CPX last week after a 95% fall
Cpx has lost money for 20yrs
Buzz off
Its an unprofitable company that will always be unprofitable. Its closer to a charity. You keep giving it money to stay afloat so that it can supposedly help other companies may some sort of meds. You buy these shares because you want to do good. Never to make money. This is a company that takes your money and gives nothing back. It will not be long before it is more dilution that keeps the gravy train running so that those in the management can take wages. If your charity minded that is fine. This companies shares will continue to get lower and lower. It is not really a going concern without constant fundraises being successful.
Hey look Aberyswyth, this share falls all on it's own. No deramp required.
You must get over this obsession you have with me ;o)
Thats a must for me Trench
I tend to disregard disproportionate movements on small volumes. You have to remember that a lot of holders on AIM these days are very nervous and don't invest longer term
Be good to see Dr Peter Sargent buy a decent chunk of shares now the interim figures have been released. That would send out a positive message to the market
DeBull that is an interesting article
GCSF is a widely used and very expensive drug. JM mentions in one of his presentations that the tool PYC is working on developing is aimed at providing guidance to clinicians on the use of GCSF, as to when would be the right circumstances to use it and when not. This could potentially be valuable in terms of optimising the use of GCSF and potentially saving money and healthcare resources for payers
The Japanese company Kyowa Kirin’s product is a GCSF drug called GRAN. This works to ‘selectively increase the count of a type of white blood cell called neutrophil, as well as increase their functional efficacy. This enables a quick recovery from neutropenia occurring as a result of cancer chemotherapy ..’
I assume that the tool PYC are developing could provide a more accurate basis and more costs effective way of prescribing GCSF than is already in the market place
The person( I assume gambler123) buys Monday 1st thing 117k and sell yesterday and 1st thing this morning
Strange
Some light reading.
https://www.linkedin.com/pulse/granulocyte-colony-stimulating-factor-g-csf-drugs-market/
The part of the article that i found interesting is "Another significant player in the market is Kyowa Kirin. This Japanese pharmaceutical company has a strong presence in the G-CSF drugs market with its product, Gran, which is used for the management of neutropenia." As far as i understand it, this is what PYC are striving for with the adaption of their dosing tool?
I did notice that Jim was rubbing his head a bit at times, but maybe he was not 100% on the day
His explanations were well thought through and meticulously explained, as has always been the case. I don't think Jim is the type to take offence and he still has so much to contribute to the business. He is still a key player here
I agree Trench
HeS made a big impact in just 6mths and I like his drive and control
Not sure how a natural speech defect can count against someone though..
Only issue i have is he does not pronounce his G's at the end of words!
Jim, looked tired and miffed, like he did not want to be at the Q&A
I think that by the time the next Q&A comes round, Peter will be flying solo.
Tweet showing Dr Sargent in front exhibitor board showing Physiomics name five times
I like this guy. He is confident and not afraid to make changes. Seems to have a clear plan for success. Good to see Peter and Jim working well together
The impatient from yesterday buys selling today .....thats all...its when the market pays you by surprise
But then sell a day later
The new permanent role was explained in Peters 3 part triangle diagram.. namely to have someone permanent to oversee the increased client work
As you say peter was excited about bio stats but also the dosing tool potential
Either no one asked about BOD buying shares, or they decided not to answer those questions?
I also found the reply about Hitesh interesting. Many will know that Hitesh is the principal consultant, but has many fingers in many pies. I take it from that, that they want someone who is 110% committed to the job & not having their time divided by System forcasting etc.
They seem genuinely excited about this Bio-statistics venture.
Particularly the 20-35min and the final 10 mins Q and a
Evening Jack
Everything today was a buy ...particularly the 1.3p and 1.34p ones
I don't post much but have quite a lot invested in PYC. I purchased another £584.05 worth of shares today at approx 11.30 am. It is showing as a sell?